1. Busting robustness: using cancer's greatest strength to our advantage. (2015) Authors: Westin, Jason R Journal: Future oncology Issue: Volume 11:Number 1(2015) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Busting robustness: using cancer's greatest strength to our advantage. (2015) Authors: Westin, Jason R Journal: Future oncology Issue: Volume 11:Number 1(2015) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Issue 3 (March 2022) Authors: Wang, Michael L; Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Nastoupil, Loretta; Fayad, Luis; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hill, Holly A; Yao, Yixin; Hagemeister, Fredrick B; Westin, Jason R; Fowler, Nathan; Samaniego, Felipe; Steiner, Raphael; Nair, Ranjit; Iyer, Swaminathan P; Nav... Journal: Lancet oncology Issue: Volume 23:Issue 3(2022) Page Start: 406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Issue 10 (October 2021) Authors: Schuster, Stephen J; Tam, Constantine S; Borchmann, Peter; Worel, Nina; McGuirk, Joseph P; Holte, Harald; Waller, Edmund K; Jaglowski, Samantha; Bishop, Michael R; Damon, Lloyd E; Foley, Stephen Ronan; Westin, Jason R; Fleury, Isabelle; Ho, P Joy; Mielke, Stephan; Teshima, Takanori; Janakiram, Mu... Journal: Lancet oncology Issue: Volume 22:Issue 10(2021) Page Start: 1403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗